PDCD1 and glioblastoma: More recently, results from a phase III clinical trial enrolling 369 patients with recurrent GBM showed that blocking PD-1 with nivolumab did not prolong median overall survival compared to bevacizumab (9.8 vs 10.0 months, P = 0.76) [5].